Evidence map›Paper›PMID 27148479›Full record

ArticleFrontiers in oncology2016

Higher Initial DNA Damage and Persistent Cell Cycle Arrest after Carbon Ion Irradiation Compared to X-irradiation in Prostate and Colon Cancer Cells.

Annelies Suetens, Katrien Konings, Marjan Moreels, Roel Quintens, Mieke Verslegers, Els Soors, Kevin Tabury, Vincent Grégoire, Sarah Baatout

Abstract read
In one paragraph

Article in Frontiers in oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Frontiers in public health · 2021
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. High LET Radiation OvercomesTechnology in cancer research & treatment · 2019
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Annelies SuetensExpert Group for Molecular and Cellular Biology, Radiobiology Unit, Belgian Nuclear Research Centre (SCK•CEN), Institute for Environment, Health and Safety, Mol, Belgium; Radiation Oncology Department, Center for Molecular Imaging, Radiotherapy and Oncology, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCL), Bruxelles, Belgium.
Katrien KoningsExpert Group for Molecular and Cellular Biology, Radiobiology Unit, Belgian Nuclear Research Centre (SCK•CEN), Institute for Environment, Health and Safety, Mol, Belgium; Laboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven, Leuven, Belgium.
Marjan MoreelsExpert Group for Molecular and Cellular Biology, Radiobiology Unit, Belgian Nuclear Research Centre (SCK•CEN), Institute for Environment, Health and Safety , Mol , Belgium.
Roel QuintensExpert Group for Molecular and Cellular Biology, Radiobiology Unit, Belgian Nuclear Research Centre (SCK•CEN), Institute for Environment, Health and Safety , Mol , Belgium.
Mieke VerslegersExpert Group for Molecular and Cellular Biology, Radiobiology Unit, Belgian Nuclear Research Centre (SCK•CEN), Institute for Environment, Health and Safety , Mol , Belgium.
Els SoorsExpert Group for Molecular and Cellular Biology, Radiobiology Unit, Belgian Nuclear Research Centre (SCK•CEN), Institute for Environment, Health and Safety , Mol , Belgium.
Kevin TaburyExpert Group for Molecular and Cellular Biology, Radiobiology Unit, Belgian Nuclear Research Centre (SCK•CEN), Institute for Environment, Health and Safety , Mol , Belgium.
Vincent GrégoireRadiation Oncology Department, Center for Molecular Imaging, Radiotherapy and Oncology, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCL) , Bruxelles , Belgium.
Sarah BaatoutExpert Group for Molecular and Cellular Biology, Radiobiology Unit, Belgian Nuclear Research Centre (SCK•CEN), Institute for Environment, Health and Safety , Mol , Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of charged-particle beams, such as carbon ions, is becoming a more and more attractive treatment option for cancer therapy. Given the precise absorbed dose-localization and an increased biological effectiveness, this form of therapy is much more advantageous compared to conventional radiotherapy, and is currently being used for treatment of specific cancer types. The high ballistic accuracy of particle beams deposits the maximal dose to the tumor, while damage to the surrounding healthy tissue is limited. In order to better understand the underlying mechanisms responsible for the increased biological effectiveness, we investigated the DNA damage and repair kinetics and cell cycle progression in two p53 mutant cell lines, more specifically a prostate (PC3) and colon (Caco-2) cancer cell line, after exposure to different radiation qualities. Cells were irradiated with various absorbed doses (0, 0.5, and 2 Gy) of accelerated (13)C-ions at the Grand Accélérateur National d'Ions Lourds facility (Caen, France) or with X-rays (0, 0.1, 0.5, 1, 2, and 5 Gy). Microscopic analysis of DNA double-strand breaks showed dose-dependent increases in γ-H2AX foci numbers and foci occupancy after exposure to both types of irradiation, in both cell lines. However, 24 h after exposure, residual damage was more pronounced after lower doses of carbon ion irradiation compared to X-irradiation. Flow cytometric analysis showed that carbon ion irradiation induced a permanent G2/M arrest in PC3 cells at lower doses (2 Gy) compared to X-rays (5 Gy), while in Caco-2 cells the G2/M arrest was transient after irradiation with X-rays (2 and 5 Gy) but persistent after exposure to carbon ions (2 Gy).

Indexed as

Caco-2carbon ion irradiationcell cycle progressionDNA double-strand break damage and repairPC3

Identifiers

PMID27148479
PMCPMC4830044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.